Repligen Corporation is a life sciences company focused on the development, production, and commercialization of products used in the process of manufacturing biological drugs. The Company's  bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. Repligen is a manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. The Company also supplies several growth factor products used to increase cell culture productivity in biomanufacturing and has developed and marketed a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. 

Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)+41%
Repligen was founded in 1981 and is headquartered in Waltham, US

Repligen Office Locations

Repligen has offices in Waltham and Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars Väg

Repligen Data and Metrics

Repligen Financial Metrics

Repligen's revenue was reported to be $30.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

30.6 m

Net income (Q1, 2017)

3.1 m

EBIT (Q1, 2017)

5.7 m

Market capitalization (21-Jul-2017)

1.4 b

Cash (31-Mar-2017)

129.7 m
Repligen's current market capitalization is $1.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.2 m63.5 m83.5 m104.5 m

Revenue growth, %

(7%)31%25%

Gross profit

45.7 m35.5 m48.3 m

Gross profit Margin, %

67%56%58%

R&D expense

7.4 m

General and administrative expense

30.9 m

Operating expense total

22.8 m24.8 m34.5 m88.6 m

EBIT

22.9 m10.7 m13.8 m16 m

EBIT margin, %

34%17%16%15%

Interest expense

27.8 k50 k32 k3.8 m

Pre tax profit

(1.6 m)11.1 m13.4 m11.7 m

Income tax expense

15.7 k3 m4.1 m11 k

Net Income

16.1 m8.2 m9.3 m11.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

15.6 m15.3 m20.8 m21.5 m19.8 m30.6 m

R&D expense

1.4 m1.6 m1.6 m1.3 m1.5 m1.5 m1.9 m1.9 m1.7 m

General and administrative expense

4.3 m4.5 m6 m6.2 m6 m7 m8.1 m7.1 m9.2 m

Operating expense total

5.8 m6.1 m7.6 m7.5 m7.4 m8.6 m10 m9 m10.9 m

EBIT

3.1 m2.2 m4 m4.6 m3.7 m3.5 m5.9 m3.7 m5.7 m

EBIT margin, %

20%15%19%21%19%19%

Interest expense

(12.8 k)(11.5 k)(9 k)(7.8 k)(8 k)(5 k)(638 k)(1.6 m)(1.6 m)

Pre tax profit

3.2 m2.3 m4.2 m4.4 m3.7 m2.5 m5.4 m2.2 m4.1 m

Income tax expense

417.8 k788.3 k1.3 m738.8 k1.1 m915 k1.5 m1.1 m999 k

Net Income

2.8 m1.5 m2.9 m3.6 m2.5 m1.6 m5.5 m6.7 m3.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.8 m35.4 m54.1 m122.2 m

Accounts Receivable

5.3 m

Inventories

1.2 m2.1 m2.1 m24.7 m

Current Assets

86.4 m80.9 m103.3 m184.2 m

PP&E

12.5 m14.5 m13.8 m15 m

Goodwill

994 k14.2 m14.3 m59.5 m

Total Assets

118.6 m128.3 m146.2 m288.9 m

Accounts Payable

1.7 m3.9 m6.7 m5.1 m

Current Liabilities

11.3 m10.7 m18.8 m21.1 m

Additional Paid-in Capital

190.6 m198.1 m202.5 m242 m

Retained Earnings

(89.1 m)(80.9 m)(71.5 m)(59.9 m)

Total Equity

103.9 m111.7 m122.7 m168.8 m

Financial Leverage

1.1 x1.1 x1.2 x1.7 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

33.8 m35.9 m31.2 m40 m48.1 m53.2 m172.6 m157.7 m129.7 m

Accounts Receivable

394.4 k523.4 k57 k331 k564 k226 k669 k

Inventories

12.8 m13.3 m12.2 m14.3 m15.9 m21.3 m23.2 m24.5 m24 m

Current Assets

73.9 m75.7 m83.5 m93.3 m96.3 m105.2 m217.9 m219.8 m185.8 m

PP&E

12.6 m13.2 m14.6 m14.5 m14 m13.6 m13.7 m14.9 m15.4 m

Goodwill

14.2 m14.1 m14.3 m14.3 m14.3 m14.3 m31 m31.2 m59.8 m

Total Assets

129 m128.8 m128.6 m137.3 m139.9 m147.3 m282.3 m285.1 m290.6 m

Accounts Payable

3.9 m2.8 m4.1 m4.3 m3 m5.1 m7.7 m5.1 m4.6 m

Current Liabilities

8.8 m10.5 m13.2 m15.8 m15.7 m15.8 m21.4 m20.2 m13.8 m

Additional Paid-in Capital

196.8 m197.5 m199.2 m200.4 m201.7 m205.1 m238.6 m240.6 m246 m

Retained Earnings

(82 m)(80.5 m)(78 m)(74.3 m)(71.8 m)(69.9 m)(66 m)(64.9 m)(56.8 m)

Total Equity

115.6 m114.6 m111.9 m118.2 m121.5 m128.9 m163.7 m166.5 m176.8 m

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.2 x1.1 x1.7 x1.7 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.6 m)8.2 m9.3 m11.7 m

Depreciation and Amortization

1.3 m4 m4.6 m5.3 m

Accounts Receivable

3.6 m(1.6 m)(3.7 m)(3.2 m)

Inventories

(870.3 k)(860.1 k)(6.1 m)(6.2 m)

Accounts Payable

247.2 k2.3 m3 m(1.8 m)

Cash From Operating Activities

2.3 m18.4 m15.1 m7.5 m

Purchases of PP&E

(575.5 k)(5.6 m)(2.6 m)(4.3 m)

Cash From Investing Activities

(5 m)(19.8 m)4.8 m(49.2 m)

Cash From Financing Activities

(330.8 k)1.7 m767 k112.1 m

Income Taxes Paid

2.5 m4.9 m4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

2.8 m1.5 m2.9 m3.6 m2.5 m1.6 m5.5 m6.7 m3.1 m

Depreciation and Amortization

1.2 m2.5 m3.8 m

Accounts Receivable

394.4 k523.4 k57 k(1.1 m)892 k(3.3 m)669 k

Inventories

12.8 m13.3 m12.2 m14.3 m15.9 m(3.1 m)(5.1 m)(6.5 m)24 m

Accounts Payable

3.9 m2.8 m4.1 m4.3 m3 m(1.6 m)511 k(1.9 m)4.6 m

Cash From Operating Activities

(3.8 m)6.8 m5.6 m

Purchases of PP&E

(431 k)(1.4 m)(3.5 m)

Cash From Investing Activities

1.2 m20 k(13.9 m)

Cash From Financing Activities

323 k111.8 m112.2 m

Income Taxes Paid

1 m2 m2.9 m
USDY, 2017

Revenue/Employee

129.6 k

Financial Leverage

1.6 x

Repligen Market Value History

Repligen Online and Social Media Presence

Repligen Company Life and Culture

You may also be interested in